Last updated: September 20, 2026
On September 17, 2026, the FDA granted clearance for a new CAR T-cell therapy clinical trial targeting adults with advanced colorectal cancer. For Phoenix-area patients in communities like Scottsdale and Tempe, this clearance, secured through a partnership with the Translational Genomics Research Institute (TGen), marks a new era of access to next-generation cancer immunotherapy without the need to travel out of state.
What Is Cancer Immunotherapy and How Does It Work?
Cancer immunotherapy is a treatment approach that reprograms or supercharges the body’s own immune system to recognize and acts on cancer cells. Unlike the immune system’s natural response, which cancer can evade, immunotherapy gives the immune system new tools, such as engineered antibodies, checkpoint inhibitors, or living cell therapies like CAR T-cells, to identify, attack, and remember cancer cells over time.
How Does Immunotherapy Differ From Chemotherapy?
Traditional chemotherapy uses drugs that kill all rapidly dividing cells, both cancerous and healthy, which explains common side effects like hair loss and nausea that affect the whole body. Immunotherapy, by contrast, acts with precision on the immune system, and its effects can deepen over time as the immune system develops lasting memory against the cancer. Patients who explore low dose chemotherapy options sometimes do so alongside immunotherapy to create a combined approach tailored to their individual diagnosis.
What Types of Cancer Can Immunotherapy Treat?
Immunotherapy was first approved for blood cancers, including leukemia and lymphoma, but it now extends to an increasing range of solid tumors. Current uses include lung cancer, melanoma, kidney cancer, bladder cancer, and colorectal cancer.
What Did the FDA Approve for CAR T-Cell Therapy in 2026?
On September 17, 2026, the FDA granted clearance for a new CAR T-cell therapy clinical trial designed specifically for adults with advanced colorectal cancer, developed by researchers at the University of Colorado Anschutz Medical Campus and manufactured at the Gates Center for Regenerative Medicine. The therapy was developed at CU Anschutz and is now moving into clinical evaluation following regulatory clearance. This trial represents the first CAR T-cell therapy directed specifically at colorectal cancer to receive FDA clearance, signaling a shift in how solid tumors are being targeted with cellular therapy.
Who Is the New CAR T-Cell Trial Designed For?
The trial targets adults with advanced colorectal cancer and children with solid tumors who have exhausted standard treatment options. Enrollment is limited to patients who meet specific clinical criteria assessed by the trial team, and all participants receive care within the structured environment of the clinical study.
What Role Does TGen Play in This Immunotherapy Development?
The Translational Genomics Research Institute, known as TGen, is a Phoenix-based partner in the therapy’s development. TGen serves as the translational research engine, bridging discoveries made in the laboratory with practical clinical applications. TGen’s co-location with City of Hope in Phoenix means that advances like this CAR T-cell trial can reach Arizona patients directly, without requiring travel to Colorado.
How Can Phoenix Patients Access CAR T-Cell Immunotherapy Trials?
For Phoenix-area patients, access to this trial begins by connecting with the TGen and City of Hope Phoenix campus, which serves as the regional hub for this study. Patients in Scottsdale, Tempe, Peoria, Glendale, and surrounding communities can inquire about enrollment through those institutions, which manage the application and screening process locally.
What Cancers Are Currently Treated With Immunotherapy in Arizona?
Arizona oncology centers offer immunotherapy across a growing range of cancers, including colorectal, breast, lung, pancreatic, ovarian, prostate, melanoma, renal, bladder, liver, gastric, esophageal, and thyroid cancers. Patients with multiple myeloma and other blood cancers have also accessed immunotherapy through regional programs. Eligibility depends on cancer type, prior treatment history, and current health status.
How Do I Know if I Qualify for Immunotherapy Trials?
Qualification for immunotherapy trials typically requires that patients have exhausted standard treatments, carry a confirmed diagnosis matching the trial’s target cancer type, and meet overall health criteria assessed by the clinical team. A physician review of medical records, imaging, and pathology reports determines eligibility. Patients are encouraged to discuss trial options during any stage of their treatment journey, as early inquiry opens more doors.
What Should I Ask My Doctor About Immunotherapy Options?
Asking about the risks, response rates, and follow-up requirements of any recommended therapy helps build a complete picture. Many patients discover that immunotherapy options were not presented unless they asked directly, making informed inquiry an essential part of advocacy.
How Do I Find a Cancer Immunotherapy Specialist Near Me?
Look for oncologists or immunotherapy specialists affiliated with research hospitals, academic medical centers, or integrated cancer treatment centers that participate in clinical trials. Facilities offering immunotherapy alongside supportive and integrative care, such as alternative uterine cancer treatments informed by immunotherapy research, often provide a broader range of options than conventional oncology alone. Checking whether a center is actively enrolling trials and offers consultation appointments is a practical first step.
What Support Services Help Patients Through Immunotherapy Treatment?
Immunotherapy treatment benefits from nutritional guidance, emotional counseling, immune-supportive therapies, and careful monitoring of side effects. Integrative centers that combine conventional treatment with supportive care help patients manage fatigue, maintain strength, and navigate the physical and emotional demands of therapy. Services like counseling, dietary planning, and complementary therapies can make a meaningful difference in overall well-being throughout treatment.
How Is EuroMed Foundation Integrating Advanced Immunotherapy Approaches?
EuroMed Foundation provides comprehensive cancer treatment services in Arizona, including integrative oncology support for patients exploring or undergoing immunotherapy. The center’s team works alongside patients and their existing oncology providers to offer complementary care designed to support immune function, manage treatment-related side effects, and enhance overall quality of life during cancer therapy.
What Holistic Support Complements Immunotherapy Treatment?
Holistic support for immunotherapy patients includes nutritional optimization, stress reduction strategies, detoxification protocols, and therapies that support immune health. The Laser Energetic Detox program and Electro-Equiscope microcurrent therapy offered at EuroMed Foundation are examples of supportive modalities that some patients incorporate alongside their primary immunotherapy regimen.
How Does the George Protocol Support Immune Health?
The George Protocol at EuroMed Foundation is an integrative treatment methodology designed to support the body’s natural defenses during and after cancer therapy. Rather than replacing conventional oncology, the George Protocol works alongside it, emphasizing immune support, metabolic health, and cellular vitality. Patients following the George Protocol receive individualized care plans developed in consultation with the medical team, with the goal of creating conditions that support the immune system’s capacity to respond to treatment.
Risks, Side Effects and Who Is Not a Candidate
CAR T-cell therapy and other cancer immunotherapies carry significant risks that patients must understand before proceeding. Acute complications include cytokine release syndrome, which causes fever, low blood pressure, and organ dysfunction, and neurologic toxicity, which may range from confusion to seizures and, in severe cases, cerebral edema. Additional risks include serious infections, prolonged low blood counts, and organ toxicities affecting the heart, liver, or kidneys. Long-term risks include secondary malignancies. Patients with active serious infections or uncontrolled organ dysfunction are generally not candidates. Anyone considering immunotherapy should discuss both the potential benefits and the full range of known risks with their treating physician.
Frequently Asked Questions
What is CAR T-cell therapy and how does it work?
CAR T-cell therapy is a form of cancer immunotherapy that reprograms a patient’s own T-cells to recognize and attack cancer cells. Blood is drawn from the patient, T-cells are engineered in a laboratory to target specific cancer markers, then infused back into the patient where they identify, attack, and develop memory against cancer cells over time.
What did the FDA approve for CAR T-cell therapy in 2026?
On September 17, 2026, the FDA granted clearance for a new CAR T-cell therapy clinical trial targeting adults with advanced colorectal cancer. Developed at the University of Colorado Anschutz Medical Campus, this marks the first CAR T-cell therapy specifically directed at colorectal cancer to receive FDA clearance.
How does immunotherapy differ from chemotherapy?
Chemotherapy uses drugs that kill all rapidly dividing cells, both cancerous and healthy, causing side effects like hair loss and nausea throughout the body. Immunotherapy acts with precision on the immune system, giving it new tools to identify and attack cancer cells specifically, with effects that can deepen over time as the immune system develops lasting memory against the cancer.
Who is eligible for the new CAR T-cell therapy clinical trial?
The trial targets adults with advanced colorectal cancer and children with solid tumors who have exhausted standard treatment options. Enrollment is limited to patients meeting specific clinical criteria assessed by the trial team, with all participants receiving care within the structured clinical study environment.
What cancers can be treated with immunotherapy?
Immunotherapy now extends to an increasing range of cancers, including lung, melanoma, kidney, bladder, colorectal, breast, pancreatic, ovarian, prostate, liver, gastric, esophageal, and thyroid cancers. Blood cancers like leukemia, lymphoma, and multiple myeloma were the first approved uses and remain important applications.
How can Phoenix-area patients access CAR T-cell immunotherapy trials?
Phoenix-area patients in Scottsdale, Tempe, Peoria, Glendale, and surrounding communities can access trials through the TGen and City of Hope Phoenix campus, which serves as the regional hub. These institutions manage the application and screening process locally, eliminating the need to travel out of state for advanced cellular therapy.
What questions should I ask my doctor about immunotherapy options?
Inquire about response rates, follow-up requirements, and risks to build a complete picture. Many patients discover immunotherapy options were not presented unless they asked directly.
This article is general information and is not medical advice. Talk to a licensed clinician about your own situation before making a treatment decision.